Oral citicoline treatment improves visual pathway function in glaucoma

Medical Science Monitor

Volumn 9, Issue 3, 2003, Pages

  Rejdak, Robert ^a   Toczołowski, Jerzy ^a   Krukowski, Jacek ^a   Kamiński, Marek ^a   Rejdak, Konrad ^a   Stelmasiak, Zbigniew ^a   Grieb, Paweł ^b,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Citicoline; Glaucoma; Visual evoked potentials

Indexed keywords

CITICOLINE; NEUROPROTECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; EVOKED RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; LATENT PERIOD; MALE; TREATMENT OUTCOME; VISUAL SYSTEM;

ADMINISTRATION, ORAL; AGED; CYTIDINE DIPHOSPHATE CHOLINE; EVOKED POTENTIALS, VISUAL; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; VISUAL PATHWAYS;

EID: 0037353345     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Nuwer MR: Fundamentals of evoked potentials and common clinical applications today. Electroenceph Clin Neurophysiol, 1998; 106: 142-8
2. Shigeto H, Tobimatsu S, Yamamoto T et al: Visual evoked cortical magnetic responses to checkerboard pattern reversal stimulation: A study on the neural generators of N75, P100 and N145. J Neurol Sci, 1998; 156: 186-94
3. Horn FK, Bergua A, Junemann A, Korth M: Visual evoked potentials under luminance contrast and color contrast stimulation in glaucoma diagnosis. J Glaucoma, 2000; 9: 428-37
4. Parisi V, Manni GL, Sgrulletta R et al: Delayed postretinal neural conduction in glaucoma patients: correlations between electrophysiological and computerized static perimetry paremeters. Acta Ophthalmol Stand Suppl, 1997; 294: 31-2
5. Parisi V, Pernini C. Guinetti C et al: Electrophysiological assessmerit of visual pathways in glaucoma. Eur. J Ophthalmol, 1997; 7: 229-35
6. Grieb P, Rejdak R: Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J Neurosci Res, 2002; 67: 143-8
7. Parisi V, Manni G, Colacino G, Bucci M. Cytidine-5′-diphosphocholine (Citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology, 1999; 106: 1126-34
8. Pecori-Giraldi J, Virno M, Covelli G et al: Therapeutic value of citicoline in tile treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol, 1989; 13: 109-12
9. Schwartz M, Belkin M, Yoles E, Solomon A: Potential treatment modalities for glaucomatous neuropathy: Neuroprotection and neuroregeneration. J Glaucoma, 1996; 5: 427-32
10. Parisi V: Neural conduction in the visual pathways in ocular hypertension and glaucoma, Graefes Arch Clin Exp Ophthalmol. 1997; 235: 136-42
11. D'Orlando KJ, Sandage BW: Citicoline (CDP-choline): Mechanisms of action and effects in ischemic brain injury. Neurol Res. 1995; 17: 281-4
12. Petkov VD, Stancheva SL, Tocuschieva L, Petkov VV: Changes in brain biogenic monoamines induced by nootropic drugs aclafenoxate and meclofenoxate and by citicholine (experiments on rats), Gen Physiol, 1990; 21: 71-5
13. Rejdak R, Toczolowski J, Solski J et al: Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Res, 2002; 34: 146-9